VYNE Therapeutics Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
VYNE Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • VYNE Therapeutics Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$13.1M, a 110% decline year-over-year.
  • VYNE Therapeutics Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$37.7M, a 24% decline year-over-year.
  • VYNE Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$29.3M, a 14.7% increase from 2022.
  • VYNE Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$34.3M, a 11.9% increase from 2021.
  • VYNE Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$38.9M, a 84.6% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$37.7M -$13.1M -$6.86M -110% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$30.8M -$10.4M -$78K -0.76% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$30.8M -$7.38M -$1.51M -25.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$29.3M -$6.83M +$1.15M +14.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-01
Q3 2023 -$30.4M -$6.23M +$3.1M +33.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$33.5M -$10.3M -$2.03M -24.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$31.5M -$5.88M +$2.82M +32.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$34.3M -$7.98M +$861K +9.73% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-01
Q3 2022 -$35.2M -$9.33M +$1.43M +13.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$36.6M -$8.29M +$1.26M +13.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$37.8M -$8.69M +$1.07M +10.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$38.9M -$8.85M +$13.1M +59.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-14
Q3 2021 -$52.1M -$10.8M +$12.7M +54.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$64.8M -$9.54M +$158M +94.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$222M -$9.76M +$30.1M +75.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$253M -$22M +$15.4M +41.3% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-04
Q3 2020 -$268M -$23.5M -$292K -1.26% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$268M -$167M -$148M -764% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$120M -$39.9M -$24M -151% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$95.9M -$37.4M +$1.37M +3.52% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-04
Q3 2019 -$97.2M -$23.2M -$9.5M -69.3% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-04
Q2 2019 -$87.7M -$19.4M -$10.2M -111% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-04
Q1 2019 -$77.6M -$15.9M -$2.66M -20.2% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-04
Q4 2018 -$74.9M -$38.8M -$29.3M -309% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-04
Q3 2018 -$45.6M -$13.7M -$5.37M -64.4% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 -$40.2M -$9.17M -$2.95M -47.4% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 -$37.3M -$13.2M -$7.67M -138% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 -$29.6M -$9.48M Oct 1, 2017 Dec 31, 2017 10-K 2020-03-03
Q3 2017 -$8.34M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 -$6.23M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-01
Q1 2017 -$5.56M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.